Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Report Overview
2023
Base Year
2018-2023
Historical Year
2024-2032
Forecast Year
Ataxia Market: Competitor Landscape
In July 2023, a global biotechnology company Biogen Inc. acquired Reata Pharmaceuticals, Inc. to accelerate the commercialization of the drug Skyclarys to patients with Friedreich’s ataxia around the world. Biogen agreed to buy Reata for USD 172.50 per share in cash, equivalent to a total enterprise value of around USD 7.3 billion. The market has been witnessing similar events of collaborations and acquisitions to deliver innovative therapies in the areas of unmet medical needs. Consequently, this is expected to propel ataxia market share in the coming years.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis AG
- Merck KGaA
- Aurobindo Pharma
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical
- Acorda Therapeutics
- Viatris Inc.
- Design Therapeutics Inc.
- Lupin
- Apotex Inc.
- Biohaven Pharmaceuticals
- Amneal Pharmaceuticals LLC.
- Biovista
- Intrabio
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Ataxia Market Report Snapshots
Ataxia Market Regional Analysis
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Key Questions Answered in the Report
The market attained a value of about USD 37.7 billion in 2023 driven by intensive research activities to develop effective drugs and therapies for ataxia patients across the 8 major markets.
The market is anticipated to grow at a CAGR of 9.72% during the forecast period of 2024-2032, likely to reach a market value of USD 95.3 billion by 2032.
The growing availability of pharmacological and other treatment alternatives like stem cell therapies to patients suffering from ataxia are the major factors aiding the market demand.
The surge in drug approvals by health authorities is one of the major trends driving the ataxia market. In February 2023, the United States Food and Drug Administration (FDA) approved Skyclarys as the first authorized treatment for Friedreich’s ataxia.
There are different types of ataxias, including spinocerebellar ataxias, ataxia-telangiectasia, and episodic ataxia, among others (multiple system atrophy (MSA)).
Based on the age group, the market is segmented into adult, child, and geriatric.
Based on the dosage forms, the market is divided into solids and liquids, among others.
The services in the market include treatment and diagnosis.
Major end users in the market include hospitals, and clinics, among others.
The major regions of the market include the United States, Japan, China, EU-4, and the United Kingdom. EU-4 is segmented into Germany, France, Italy, and Spain.
Key players involved in the market are Novartis AG, Merck KGaA, Aurobindo Pharma, Pfizer Inc., Sanofi, Teva Pharmaceutical, Acorda Therapeutics, Viatris Inc., Design Therapeutics Inc., Lupin, Apotex Inc., Biohaven Pharmaceuticals, Amneal Pharmaceuticals LLC., Biovista, and Intrabio.
Purchase Full Report
Datasheet
- Selected Sections, One User
- Printing Not Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Single User License
One User
- All Sections, One User
- One Print Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
Five Users
- All Sections, Five Users
- Five Prints Allowed
- Email Delivery in PDF
- Free Limited Customisation
- Post Sales Analyst Support
50% Discount on Next Update
Corporate License
Unlimited Users
- All Sections, Unlimited Users
- Unlimited Prints Allowed
- Email Delivery in PDF + Excel
- Free Limited Customisation
- Post Sales Analyst Support
- 50% Discount on Next Update
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Our Offices
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124